# OnCo record endometrial-p53-abnormal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/endometrial-p53-abnormal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "endometrial-p53-abnormal" ;
  schema:name "p53-abnormal endometrial cancer, including uterine serous carcinoma"@en ;
  schema:alternateName "p53abn endometrial cancer"@en, "Copy-number-high endometrial cancer"@en, "Uterine serous carcinoma"@en, "Uterine papillary serous carcinoma"@en, "Serous-like endometrial cancer"@en ;
  schema:description "p53-abnormal endometrial cancer is the aggressive class, dominated by serous carcinoma, whose cells have lost the p53 guardian gene and carry scrambled chromosomes. It is the one group that clearly gains from adding chemotherapy to radiotherapy after surgery, and about a quarter of serous tumours overexpress HER2, which trastuzumab and trastuzumab deruxtecan can target."@en ;
  schema:url <https://onco.cc/cancers/endometrial-p53-abnormal/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Uterine_serous_carcinoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Uterine_serous_carcinoma> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/trials/nct06989112/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/ideas/idea-her2-adc-serous-endometrial/>, <https://onco.cc/targets/wee1/>, <https://onco.cc/targets/atr/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  onco:standardOfCare <https://onco.cc/terms/hysterectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/trials/portec-3/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-pantumor02/>, <https://onco.cc/targets/her2/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/ruby/>, <https://onco.cc/trials/keynote-775/> .